M&A / Deals MSD concludes Terns acquisition to expand CML pipeline Pharmaceutical TechnologyMSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).HematologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Expands Market Access, Authorizes New ENDS ProductsNext: MSD concludes Terns acquisition to expand CML pipeline Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
